Wednesday, July 8, 2026

pharma · Hypercholesterolemia · Hyperlipidemia · ESPR

Esperion Therapeutics

Espervita Therapeutics is a pharma organization headquartered in ann arbor, USA. It trades on NYSE under ticker ESPR. Primary therapeutic focus areas include Hypercholesterolemia, Hyperlipidemia, Cardiovascular Diseases,

Ann Arbor, US HQ
5 Employees
Public company Type
ESPR · NYSE Ticker
Company details
Status
Public
HQ
Ann Arbor, US
Employees
5
Programs
15
Drugs
9
Patents
55
Clinical program

Bempedoic Acid + Ezetimibe Fixed-Dose Combination

Phase 3 · other · Hyperlipidemias

Bempedoic Acid + Ezetimibe Fixed-Dose Combination for Hyperlipidemias is a Phase 3 program (other) at Esperion Therapeutics with 1 ClinicalTrials.gov record(s).

Internal code 1002FDC-053

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Esperion Therapeutics
Phase
Phase 3
Modality
other
Indication
Hyperlipidemias
Status
completed
Trials
1